NasdaqCM - Delayed Quote • USD
Forte Biosciences, Inc. (FBRX)
At close: April 24 at 4:00 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Cash Flow
-28,706.0000
-28,706.0000
-8,185.0000
-16,677.0000
-18,423.0000
Investing Cash Flow
47.0000
47.0000
--
--
3,582.0000
Financing Cash Flow
24,684.0000
24,684.0000
7,241.0000
-44.0000
66,667.0000
End Cash Position
37,125.0000
37,125.0000
41,100.0000
42,044.0000
58,765.0000
Capital Expenditure
-88.0000
-88.0000
--
--
--
Issuance of Capital Stock
24,728.0000
24,728.0000
7,229.0000
--
66,699.0000
Free Cash Flow
-28,794.0000
-28,794.0000
-8,185.0000
-16,677.0000
-18,423.0000
12/31/2020 - 4/13/2017
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ZH6.BE BIOHAVEN LTD
40.00
+5.82%
AKTX Akari Therapeutics, Plc
1.1900
-2.46%
EVAX Evaxion Biotech A/S
4.1300
-0.24%
NAMSW NewAmsterdam Pharma Company N.V.
10.53
+2.73%
EFTRW eFFECTOR Therapeutics, Inc.
0.0200
-19.68%
QLGN Qualigen Therapeutics, Inc.
0.3089
-1.94%
PULM Pulmatrix, Inc.
2.0201
-3.34%
COEP Coeptis Therapeutics Holdings, Inc.
0.3270
-2.39%
QNRX Quoin Pharmaceuticals, Ltd.
0.6321
-5.30%
NRXS NeurAxis, Inc.
3.0000
+6.38%